1. Antithrombotic Therapy in AF Patients Undergoing PCI

3. Epidemiology

4. How to Reduce the Probability of a Major Bleeding Complication?

5. Patients with AF Undergoing PCI Meta-Analysis – NOACs vs VKA

6. ENTRUST-AF PCI Study Design

7. ENTRUST-AF PCI Outcomes

8. ENTRUST-AF PCI Edoxaban Dose Reduction Criteria

9. ENTRUST-AF PCI Landmark Analysis for Primary Endpoint After Day 14

10. Meta-Analysis of DAPT vs TAPT Stent Thrombosis

11. Recommendations for OAC and Antiplatelet Therapy in AF Undergoing PCI

12. ENTRUST-AF PCI Baseline Patient Characteristics

13. WOEST VKA in Patients With AF Undergoing PCI

14. Network of 4 Antithrombotic Treatment Regimens

15. What Have We Learned?

16. Selecting a NOAC

17. PIONEER Incidence of MACEs With Rivaroxaban vs VKA

18. RE-DUAL Efficacy Endpoints for Dabigatran vs VKA

19. What Next?

20. Abbreviations

21. Abbreviations (cont)